

Amendments to the Claims

This listing of claims replaces all prior versions and listings of claims in the application.

Listing of Claims

1. (Currently Amended) ~~The use of~~ A method for treatment of allergy by hyposensitization, comprising administering a conjugate of hydroxyalkylstarch and an allergen ~~in which~~ to an allergy sufferer, wherein at least one hydroxyalkylstarch is covalently coupled to the allergen ~~for hyposensitization.~~
2. (Currently Amended) ~~The use as claimed in~~ method of claim 1, where the hydroxyalkylstarch is coupled directly or via a linker to the allergen.
3. (Currently Amended) ~~The use as claimed in~~ method of claim 1, where the hydroxyalkylstarch is hydroxyethylstarch, hydroxypropylstarch or hydroxybutylstarch.
4. (Currently Amended) ~~The use as claimed in~~ method of claim 1, in which the hydroxyalkylstarch is hydroxyethylstarch ~~has~~ having an average molecular weight of from 1 to 300 kDa.
5. (Currently Amended) ~~The use as claimed in~~ method of claim 1, in which the hydroxyalkylstarch is hydroxyethyl starch ~~has~~ having a level of molar substitution of from 0.1 to 0.8 and a C2:C6 substitution ratio in the range from 2 to 20, in each case based on the hydroxyethyl groups.
6. (Currently Amended) ~~The use as claimed in~~ method of claim 1, in which the allergen ~~has been~~ is selected from the group consisting of polypeptides ~~or~~ and proteins.
7. (Currently Amended) ~~The use as claimed in~~ method of claim 1, in which the allergen is a glycoprotein.

8. (Currently Amended) The ~~use as claimed in~~ method of claim 1 ~~6~~, in which the hydroxyalkylstarch is coupled to the polypeptide chain ~~or to one or more of the saccharide chains of the glycoprotein.~~

9. (Currently Amended) The ~~use according to~~ method of claim 1, ~~for hyposensitization of wherein said allergy sufferers~~ sufferer is a subject in whom an IgE-mediated sensitization is detected or whose clinical symptoms have been observed.

10. (Currently Amended) The ~~use as claimed in~~ method of claim 1 ~~11~~, where the ~~specific immunotherapy~~ hyposensitization is employed for the therapy of allergies to pollen, mites, mammalian hair (~~saliva~~), mammalian saliva, fungi, insects, foods, ~~and natural rubber, or natural~~ latex.

11. (Currently Amended) The ~~use as claimed in~~ method of claim 1, where the ~~therapy~~ hyposensitization is employed for the treatment of asthmatics, hay-fever patients and patients showing other types of clinically relevant reactions to immediate-type allergens.

12. (Currently Amended) The ~~use as claimed in~~ method of claim 1, where said administration to said allergy sufferer takes place subcutaneously, mucosally, orally, perorally or sublingually.

13. (Currently Amended) The ~~use as claimed in~~ method of claim 1, where the ~~immunotherapy~~ hyposensitization is carried out preseasonally or perennially for airborne allergens.

14. (Currently Amended) The ~~use as claimed in~~ method of claim 1, where the ~~immunotherapy~~ hyposensitization is carried out for people allergic to insects in the rush or ultra-rush method.

15. (Currently Amended) The ~~use as claimed in~~ method of claim 1, in which the hydroxyalkylstarch is hydroxyethylstarch ~~has~~ having an average molecular weight of from 5 to 200 kDa.

16. (New) The method of claim 7, wherein the hydroxyalkylstarch is coupled to the polypeptide chain or to one or more of the saccharide chains of the glycoprotein.